Toshifumi Tada

Response to the Letter Regarding "Methodological Considerations in Real-World Evaluation of Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma".

Journal: Journal of gastroenterology and hepatology

Published: August 04, 2026

Response to the Letter Regarding "Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial".

Journal: Journal of gastroenterology and hepatology

Published: July 29, 2026

Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: May 29, 2026

Early LMR Dynamics and AFP Status in Advanced HCC Treated With Atezolizumab/Bevacizumab.

Journal: Anticancer research

Published: May 23, 2026

Efficacy of Lenvatinib as Subsequent Therapy After Combination Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma.

Journal: Anticancer research

Published: May 14, 2026

Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.

Journal: Oncology

Published: April 19, 2026

Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: April 07, 2026

Identifying a biologically high-risk subgroup of anatomically resectable hepatocellular carcinoma.

Journal: Hepatology international

Published: March 22, 2026

Ablation-Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: March 17, 2026

Response to 'Letter to the Editor: "Lymphocyte-Monocyte Ratio Predicts Survival in Patients With Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab: A Multicenter Analysis"'.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: February 12, 2026

Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 07, 2026

Superior Efficacy of Tenofovir Alafenamide Compared With Entecavir in Reducing Hepatitis B Surface Antigen: A Multicentre Propensity Score-Matched Study Using Linear Mixed-Effects Models.

Journal: Alimentary pharmacology & therapeutics

Published: February 05, 2026

Response to the Letter Regarding "Methodological Considerations in Real-World Evaluation of Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma".

Response to the Letter Regarding "Methodological Considerations in Real-World Evaluation of Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma".

Response to the Letter Regarding "Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial".

Response to the Letter Regarding "Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial".

Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.

Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.

Early LMR Dynamics and AFP Status in Advanced HCC Treated With Atezolizumab/Bevacizumab.

Early LMR Dynamics and AFP Status in Advanced HCC Treated With Atezolizumab/Bevacizumab.

Efficacy of Lenvatinib as Subsequent Therapy After Combination Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma.

Efficacy of Lenvatinib as Subsequent Therapy After Combination Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma.

Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.

Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.

Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.

Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.

Identifying a biologically high-risk subgroup of anatomically resectable hepatocellular carcinoma.

Identifying a biologically high-risk subgroup of anatomically resectable hepatocellular carcinoma.

Ablation-Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma.

Ablation-Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma.

Response to 'Letter to the Editor: "Lymphocyte-Monocyte Ratio Predicts Survival in Patients With Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab: A Multicenter Analysis"'.

Response to 'Letter to the Editor: "Lymphocyte-Monocyte Ratio Predicts Survival in Patients With Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab: A Multicenter Analysis"'.

Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab.

Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab.

Superior Efficacy of Tenofovir Alafenamide Compared With Entecavir in Reducing Hepatitis B Surface Antigen: A Multicentre Propensity Score-Matched Study Using Linear Mixed-Effects Models.

Superior Efficacy of Tenofovir Alafenamide Compared With Entecavir in Reducing Hepatitis B Surface Antigen: A Multicentre Propensity Score-Matched Study Using Linear Mixed-Effects Models.

Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab.

Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab.